Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

254 ARTÍCULOS , VIENDO DEL 16 AL 30

A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment

Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT, Wingo TS, Hales CM, Gámez Tansey M, Goldstein DS, Abrol A, Calhoun VD, Goldstein FC, Hajjar I, Fagan AM, Galasko D, Edland SD, Hanfelt J, Lah JJ, Weinshenker D.

Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452.

Potential Roles of α-amylase in Alzheimer's Disease: Biomarker and Drug Target

Chen WN, Tang KS, Yeong KY.

Curr Neuropharmacol. 2022;20(8):1554-1563. doi: 10.2174/1570159X20666211223124715.

Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease

Creese B, Ismail Z.

Alzheimers Res Ther. 2022 Jan 5;14(1):2. doi: 10.1186/s13195-021-00949-7.

Exosomes-Potential for Blood-Based Marker in Alzheimer's Disease

Li CC, Hsu WF, Wo AM.

Acta Neurol Taiwan. 2022 Jan 25;31(1):1-6.

Imaging biomarkers for Alzheimer's disease and glaucoma: Current and future practices

Martucci A, Picchi E, Di Giuliano F, Pocobelli G, Mancino R, Toschi N, Russo R, Floris R, Garaci F, Nucci C.

Curr Opin Pharmacol. 2022 Feb;62:137-144. doi: 10.1016/j.coph.2021.12.003. Epub 2022 Jan 4.

Probiotic supplementation demonstrates therapeutic potential in treating gut dysbiosis and improving neurocognitive function in age-related dementia

Meng HYH, Mak CCH, Mak WY, Zuo T, Ko H, Chan FKL.

Eur J Nutr. 2022 Jun;61(4):1701-1734. doi: 10.1007/s00394-021-02760-4. Epub 2022 Jan 10.

Promising protein biomarkers in the early diagnosis of Alzheimer's disease

Sharma L, Sharma A, Kumar D, Asthana MK, Lalhlenmawia H, Kumar A, Bhattacharyya S, Kumar D.

Metab Brain Dis. 2022 Aug;37(6):1727-1744. doi: 10.1007/s11011-021-00847-9. Epub 2022 Jan 11.

Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease

Jiang J, Wang M, Alberts I, Sun X, Li T, Rominger A, Zuo C, Han Y, Shi K, Initiative FTADN.

Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2163-2173. doi: 10.1007/s00259-022-05687-y. Epub 2022 Jan 15.

Interactions Between Weight Loss and Plasma Neurodegenerative Markers for Determining Cognitive Decline Among Community-Dwelling Older Adults

Giudici KV, Guyonnet S, Morley JE, Nguyen AD, Aggarwal G, Parini A, Li Y, Bateman RJ, Vellas B, de Souto Barreto P; MAPT/DSA Group.

J Gerontol A Biol Sci Med Sci. 2022 Jun 1;77(6):1159-1168. doi: 10.1093/gerona/glac015.

Biomarkers with Plasma Amyloid β and Tau Protein Assayed by Immunomagnetic Reduction in Patients with Amnestic Mild Cognitive Impairment and Alzheimer's Disease

Lee PJ, Tsai CL, Liang CS, Peng GS, Lee JT, Tsai CK, Lin YK, Yang FC.

Acta Neurol Taiwan. 2022 Jun 30;31(2):53-60.

Soluble TREM2: Innocent bystander or active player in neurological diseases?

Filipello F, Goldsbury C, You SF, Locca A, Karch CM, Piccio L.

Neurobiol Dis. 2022 Apr;165:105630. doi: 10.1016/j.nbd.2022.105630. Epub 2022 Jan 15.

Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study

Chhatwal JP, Schultz SA, McDade E, Schultz AP, Liu L, Hanseeuw BJ, Joseph-Mathurin N, Feldman R, Fitzpatrick CD, Sparks KP, Levin J, Berman SB, Renton AE, Esposito BT, Fernandez MV, Sung YJ, Lee JH, Klunk WE, Hofmann A, Noble JM, Graff-Radford N, Mori H, Salloway SM, Masters CL, Martins R, Karch CM, Xiong C, Cruchaga C, Perrin RJ, Gordon BA, Benzinger TLS, Fox NC, Schofield PR, Fagan AM, Goate AM, Morris JC, Bateman RJ, Johnson KA, Sperling RA; Dominantly Inherited Alzheimer's Network Investigators.

Lancet Neurol. 2022 Feb;21(2):140-152. doi: 10.1016/S1474-4422(21)00375-6.

Prospects for the use of graphene-based biological sensors in the early diagnosis of Alzheimer's disease (review of literature)

Vorobev SV, Yanishevskij SN, Emelin AY, Lebedev AA, Lebedev SP, Makarov YN, Usikov AS, Klotchenko SA, Vasin AV.

Klin Lab Diagn. 2022 Jan 21;67(1):5-12. doi: 10.51620/0869-2084-2022-67-1-5-12.

Blood biomarkers may distinguish among dementia disorders

Parnetti L, Paolini Paoletti F, Gaetani L.

J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):571. doi: 10.1136/jnnp-2021-328649. Epub 2022 Jan 25.

Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial

Kellar D, Register T, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, Craft S.

Sci Rep. 2022 Jan 25;12(1):1346. doi: 10.1038/s41598-022-05165-3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias